ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Lilly Will Invest $350 Million in China Diabetes Cartridge Facility
publication date: Nov 14, 2013
Lilly announced it will spend $350 million in China to increase its production of insulin cartridges. The company emphasized that China is home to the world’s largest population of diabetics – which numbers almost 100 million now and is expected to grow as China’s population adopts western lifestyles. The China investment is part of a larger $1 billion building projects that Lilly has announced since the beginning of the year to increase diabetes drug capacity. More details....
Stock Symbol: (NYSE: LLY)
Share this with colleagues:
This article is available for purchase - please click here for details.
Sorry this page is available to subscribers only. If you're not a subscriber why not subscribe today?